Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer And GSK Call For Early Risk Tests; Sign Of Further Vioxx Fallout?

Executive Summary

GlaxoSmithKline will launch a risk assessment program that will allow company researchers to more rapidly recognize safety signals

You may also be interested in...

Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return

Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor

Zeldox Bold Interaction Warning, Not Black Box, Needed For QTc - Committee

Labeling for Pfizer's Zeldox (ziprasidone) should clearly warn against combination use with other drugs that may prolong the QTc interval, but a black box may not be necessary, FDA's Psychopharmacological Drugs Advisory Committee suggested July 19.

Pfizer Discussing Trovan Labeling With FDA; Hepatic Injuries "Unpredictable"

The unpredictability of liver injuries associated with use of Trovan (trovafloxacin) is the challenge facing Pfizer and the probable point-of-departure for discussions with FDA.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts